LEXINGTON, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq:ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it entered into a pilot program agreement with TriMetis Life Sciences, LLC (“TriMetis”), a provider of digital pathology, laboratory and AI workflow and automation solutions for hospitals, pathology, diagnostic and pharmaceutical companies. This agreement aims to establish a strategic partnership between iSpecimen and TriMetis, providing opportunities for iSpecimen, its suppliers and customers to utilize technology solutions from TriMetis.

Read more at globenewswire.com

Related news for (ISPC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.